University of Geneva spinout Amal Therapeutics has added $9.6m to its coffers following a series B round backed by Boehringer Ingelheim and Helsinn.
Amal Therapeutics, a Switzerland-based cancer-focused biotechnology spinout from University of Geneva, has raised SFr8.8m ($9.6m) in a series B round co-led by pharmaceutical firm Boehringer Ingelheim.
The corporate, which participated through its corporate venturing division Boehringer Ingelheim Venture Fund, co-led the round with Helsinn Investment Fund, the strategic investment arm of pharmaceutical firm Helsinn, and BioMedPartners.
German public-private partnership High-Tech Gründerfonds (HTGF) also took part in the round, as did VI Partners and Schroder Adveq.
The funding constitutes a first…
